GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin stock rose after the FDA aligned on key elements of belapectin's phase III MASH cirrhosis program, reducing regulatory uncertainty and clarifying a potential path to full approval. The update is a meaningful de-risking event for the company’s lead asset, though no approval or efficacy data were announced. The news is likely supportive for the shares and could move the stock in the near term.

Analysis

Galectin stock rose after the FDA aligned on key elements of belapectin's phase III MASH cirrhosis program, reducing regulatory uncertainty and clarifying a potential path to full approval. The update is a meaningful de-risking event for the company’s lead asset, though no approval or efficacy data were announced. The news is likely supportive for the shares and could move the stock in the near term.